Indacaterol: In chronic obstructive pulmonary disease

Drugs

Volumn 70, Issue 17, 2010, Pages 2269-2280

  Moen, Marit D ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Chronic obstructive pulmonary disease; Indacaterol, general; Research and development

Indexed keywords

FORMOTEROL; INDACATEROL; ONBREZ; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COUGHING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; MAINTENANCE THERAPY; MUSCLE SPASM; POTASSIUM BLOOD LEVEL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SYMPTOM; TACHYCARDIA; TREATMENT DURATION; TREMOR; UPPER RESPIRATORY TRACT INFECTION;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANIMALS; CLINICAL TRIALS, PHASE III AS TOPIC; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; VASODILATOR AGENTS;

EID: 78449291452     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11203960-000000000-00000     Document Type: Review

References (48)

1. Halbert RJ, Natoli JL, Gano A, et al. Global burden ofCOPD: systematic review and meta-analysis. Eur Respir J 2006 Sep; 28 (3): 523-32.
2. Celli BR, Thomas NE, Anderson JA, et al. Effect ofpharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008 Aug 15; 178 (4): 332-8.
3. Onbrez Breezhaler (indacaterol) 150 and 300 micrograminhalation powder, hard capsules: EU summary of product characteristics. West Sussex, UK: Novartis Europharm Limited, 2009.
4. Scola AM, Loxham M, Charlton SJ, et al. The long-actingb-adrenoceptor agonist, indacaterol, inhibits IgE-dependent responses of human lung mast cells. Br J Pharmacol 2009; 158: 267-76.
5. 2 adreno-ceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 2006 May; 317 (2): 762-70.
6. 2-agonist, on isolated human bronchi. Eur Respir J 2007 Mar; 29 (3): 575-81.
7. 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther 2008 Jan; 324 (1): 270-5.
8. Lombardi D, Cuenoud B, Kramer SD. Lipid membrane in-teractions of indacaterol and salmeterol: do they influence their pharmacological properties? Eur J Pharm Sci 2009 Dec 8; 38 (5): 533-47.
9. 2- adrenoceptor agonists. Naunyn Schmiede-bergs Arch Pharmacol 2010 Sep; 382 (3): 255-63.
10. Tsagaraki V, Amfilochiou A, Markantonis SL. Evidence oftachyphylaxis associated with salmeterol treatment of chronic obstructive pulmonary disease patients. Int J Clin Pract 2006 Apr; 60 (4): 415-21.
11. Haney S, Hancox RJ. Recovery from bronchoconstrictionand bronchodilator tolerance. Clin Rev Allergy Immunol 2006 Oct-Dec; 31 (2-3): 181-96.
12. 2-agonistsin patients with asthma. J Am Osteopath Assoc 2006 Sep; 106 (9): 562-7.
13. 2- adrenoceptoragonists: an emerging therapeutic option for asthma and COPD? Drugs 2007; 67 (4): 503-15.
14. Battram C, Li J, Coulthard A, et al. Indacaterol does notblunt the effect of salbutamol in vivo [abstract no. A2075]. Am J Respir Crit Care Med 2009; 179.
15. Rennard S, Bantje T, Centanni S, et al. A dose-ranging studyof indacaterol in obstructive airways disease, with a tio-tropium comparison. Respir Med 2008 Jul; 102 (7): 1033-44.
16. Bauwens O, Ninane V, Van de Maele B, et al. 24-hourbronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and for-moterol. Curr Med Res Opin 2009 Feb; 25 (2): 463-70.
17. Feldman G, Siler T, Prasad N, et al. Efficacy and safety ofindacaterol 150mg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010; 10: 11.
18. Beier J, Beeh K-M, Brookman L, et al. Bronchodilator ef-fects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther 2009 Dec; 22 (6): 492-6.
19. LaForce C, Aumann J, de Teresa Parreno L, et al. Sustained24-hour efficacy of once daily indacaterol (300 mg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study. Pulm Pharmacol Ther. Epub 2010 Jul 7.
20. 2-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther 2007; 20(6): 740-9.
21. Vogelmeier C, Ramos-Barbon D, Jack D, et al. Indacaterolprovides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res 2010 Oct 5; 11 (1): 135.
22. Balint B, Watz H, Amos C, et al. Onset of action of in-dacaterol in patients with COPD: comparison with salbu-tamol and salmeterol-fluticasone. Int J Chron Obstruct Pulmon Dis 2010; 5: 311-8.
23. Magnussen H, Verkindre C, Jack D, et al. Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. Respir Med. Epub 2010 Sep 16.
24. O'Donnell DE, Casaburi R, Swales J, et al. Effect of in-dacaterol on exercise endurance in patients with moderate-to-severe COPD [abstract no. F68]. Am J Respir Crit Care Med 2010; 181: A4431.
25. Beeh K-M, Khindri S, Eeg M, et al. Effect of indacaterolmaleate on dynamic lung hyperinflation in patients with COPD [abstract no. E4357]. 19th Annual Congress of the European Respiratory Society; 2009 Sep 12-16; Vienna.
26. 2-adreno-ceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 2005; 65 (12): 1595-610.
27. Beier J, Bantje T, Owen R, et al. Cardiac safety of indacaterol,a novel once-daily bronchodilator, in COPD [abstract no. P3611]. Eur Respir J 2008 Oct; 32 Suppl. 52: 631s.
28. Khindri S, Sabo R, Harris S, et al. Cardiac safety of in-dacaterol - no clinical effect on QT in healthy subjects[abstract no. P2031]. 19th Annual Congress of the European Respiratory Society; 2009 Sep 12-16; Vienna.
29. Perry S, Woessner R, Kaiser G, et al. Pharmacokinetics ofindacaterol after single and multiple inhaled doses [abstract no. F57]. Am J Respir Crit Care Med 2010; 181: A4420.
30. Plus poster presented at the 106th International Conference of the American Thoracic Society; 2010 May 14-19; New Orleans (LA).
31. European Medicines Agency. Assessment report for OnbrezBreezhaler [online]. Available from URL: http://www.ema. europa.eu/humandocs/PDFs/EPAR/ onbrez-breezhaler/H-1114-en6.pdf [Accessed 2010 Jan 22].
32. Donohue JF, Fogarty C, Lotvall J, et al. Once-dailybronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182 (2): 155-62.
33. 2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010 Jun; 65 (6): 473-9.
34. Kornmann O, Dahl R, Centanni S, et al. Once-daily in-dacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. Epub 2010 Aug 6.
35. Korn S, Kerwin E, Atis S, et al. Indacaterol once-dailyprovides superior efficacy to salmeterol: a 12-week trial [abstract plus poster]. 20th Annual Congress of the European Respiratory Society; 2010 Sep 18-22; Barcelona.
36. Novartis clinical trial results database. A 12 week treatment,multi- center, randomized, parallel group, double blind, double dummy study to assess the superiority of in-dacaterol (150mg o.d.) via a SDDPI in patients with moderate to severe COPD, using salmeterol (50mg b.i.d.) as an active comparator delivered via a DISKUS inhaler [online]. Available from URL http://www.novctrd. com [Accessed 2010 Oct 13].
37. Barnes PJ, Pocock SJ, Magnussen H, et al. Integrating in-dacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther 2010 Jun; 23 (3): 165-71.
38. Rennard SI, Chapman KR, Luthra A, et al. Once-daily in-dacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD) [abstract]. 75th Annual Meeting of the American College of Chest Physicians; 2009 Oct 31-Nov 5; San Diego (CA).
39. Mahler DA, Buhl R, Owen R, et al. Indacaterol provideseffective bronchodilation in patients with chronic ob-structive pulmonary disease irrespective of patient age Donohue JF, Decramer M, Owen R, et al.Indacaterol pro-vides significant bronchodilation in patients with chronic obstructive pulmonary disease irrespective of concomitant inhaled corticosteroid use [abstract no. F75].Am J Respir Crit Care Med2010;181:A4438.
40. Plus poster presented at the 106th International Conference of the American Thoracic Society; 2010 May 14-19; New Orleans (LA).
41. Kleerup EC, D'Urzo A, Owen R, et al. Once-daily in-dacaterol provides significant bronchodilation in chronic obstructive pulmonary disease patients irrespective of baseline reversibility [abstract no. F76]. Am J Respir Crit Care Med 2010; 181: A4439.
42. Plus poster presented at the 106th International Conference of the American Thoracic Society; 2010 May 14-19; New Orleans (LA).
43. Siler TM, Williams J, Yegen U, et al. The effect of once-dailyindacaterol on health-related quality of life, rescue medication use, and exacerbation rates in patients with moderate-to-severe COPD: a pooled analysis of three months of treatment. Am J Respir Crit Care Med 2010; 181: A4430.
44. Plus poster presented at the 106th International Conference of the American Thoracic Society; 2010 May 14-19; New Orleans (LA).
45. Kleerup E, Williams J, Yegen U, et al. The effect of in-dacaterol once-daily on health-related quality of life, symptoms and rescue medication use in moderate-to-severe chronic obstructive pulmonary disease: pooled analysis of six month data [abstract no. F66]. Am J Respir Crit Care Med 2010; 181: A4429.
46. Plus poster presented at the 106th International Conference of the American Thoracic Society; 2010 May 14-19; New Orleans (LA).
47. Cazzola M, Matera MG. Novel long-acting bronchodilatorsfor COPD and asthma. Br J Pharmacol 2008 Oct; 155 (3): 291-9.
48. 2-adrenoreceptor agonist. Open Respir Med J 2009; 3: 27-30